Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Results From the PAKT Trial
2018 ASCO Annual MeetingPeter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).
Related Videos
Toni K. Choueiri, MD, and Lauren C. Harshman, MD on RCC: Results From the PROSPER Trial
Toni K. Choueiri, MD, and Lauren C. Harshman, MD, both of Dana-Farber Cancer Institute, discuss phase III study findings on perioperative nivolumab vs observation ...
David F. McDermott, MD, on RCC: Results of the KEYNOTE-427 Trial
David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carci...
Gabriel N. Hortobagyi, MD, on Breast Cancer Staging: New and Important Changes
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based o...
Juliet Elizabeth Wolford, MD, on Ovarian Cancer: The Cost of Care
Juliet Elizabeth Wolford, MD, of the University of California, Irvine, discusses the cost-effectiveness of various types of maintenance therapy in advanced ovarian cancer: paclitax...
Toni K. Choueiri, MD, and Jonathan E. Rosenberg, MD: Bladder Cancer Roundup
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the ...
